Stockreport

Lumos Pharma Announces Clinical Updates

Lumos Pharma, Inc.  (LUMO) 
PDF OraGrowtH210 Trial in PGHD primary outcome 6-month data now anticipated in 2H2023; treatment period to be extended to 12 monthsOraGrowtH212 PK/PD Trial initiated in Q2 2 [Read more]